Encouraging Survival Data in Patients with Metastatic CRC Previously Treated with Leronlimab Announced July 8, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Ph 3 July 8, 2025
Presentation of positive Ph 1b data for givastomig, nivolumab, and mFOLFOX6 combo in 1L gastric cancer patients announced July 8, 2025
NMPA clears application to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab in 1L metastatic HCC patients July 8, 2025
EC granted conditional marketing authorization for Ziihera® (zanidatamab) monotherapy for unresectable locally advanced or metastatic previously treated HER2-positive biliary tract cancer July 8, 2025
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial of Certepetide + SoC chemo combo in Metastatic Pancreatic Cancer announced July 1, 2025
Revolution Medicines and Summit Therapeutics to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors July 1, 2025
Ph 3 FORTITUDE-101 of 1L bemarituzumab plus chemotherapy (mFOLFOX6) in gastric cancer patients met primary endpoint of OS July 1, 2025
First patient dosed in Ph 1/2 trial of TNG462 and daraxonrasib or zoldonrasib in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer July 1, 2025
Updated data from Ph 2 DeFianCe study of sirexatamab (DKN-01) + bevacizumab and chemo combo shows statistically significant PFS improvements in DKK1-high, VEGF-naïve and liver mets MSS colorectal cancer patients July 1, 2025
Positive OS Data for Atebimetinib (IMM-1-104) from Ph 2a Trial in 1L Pancreatic Cancer Patients Reported June 24, 2025
Zanzalintinib + Tecentriq Combination Improved OS in STELLAR-303 Ph 3 Pivotal Trial in Patients with Metastatic CRC June 24, 2025
FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations June 24, 2025
FDA grants Orphan Drug Designation to ADoBind MC001 for the treatment of pancreatic cancer June 24, 2025
Positive Biomarker and Machine Learning Data from Ph 2 Elraglusib Trial in 1L Treatment of Metastatic Pancreatic Cancer Announced June 24, 2025
First Patient dosed in Ph 1 Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC) June 17, 2025
Ph 3 Data for Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet June 17, 2025
